Cargando…
Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
Advancement in sequencing technologies allows for the identification of molecular pathways involved in tumor progression and treatment resistance. Implementation of novel agents targeting these pathways, defined as targeted therapy, significantly improves the prognosis of cancer patients. Targeted t...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694302/ https://www.ncbi.nlm.nih.gov/pubmed/36432631 http://dx.doi.org/10.3390/pharmaceutics14112442 |
_version_ | 1784837766176047104 |
---|---|
author | Liguori, Luigi Polcaro, Giovanna Nigro, Annunziata Conti, Valeria Sellitto, Carmine Perri, Francesco Ottaiano, Alessandro Cascella, Marco Zeppa, Pio Caputo, Alessandro Pepe, Stefano Sabbatino, Francesco |
author_facet | Liguori, Luigi Polcaro, Giovanna Nigro, Annunziata Conti, Valeria Sellitto, Carmine Perri, Francesco Ottaiano, Alessandro Cascella, Marco Zeppa, Pio Caputo, Alessandro Pepe, Stefano Sabbatino, Francesco |
author_sort | Liguori, Luigi |
collection | PubMed |
description | Advancement in sequencing technologies allows for the identification of molecular pathways involved in tumor progression and treatment resistance. Implementation of novel agents targeting these pathways, defined as targeted therapy, significantly improves the prognosis of cancer patients. Targeted therapy also includes the use of monoclonal antibodies (mAbs). These drugs recognize specific oncogenic proteins expressed in cancer cells. However, as with many other types of targeting agents, mAb-based therapy usually fails in the long-term control of cancer progression due to the development of resistance. In many cases, resistance is caused by the activation of alternative pathways involved in cancer progression and the development of immune evasion mechanisms. To overcome this off-target resistance, bispecific antibodies (bsAbs) were developed to simultaneously target differential oncogenic pathway components, tumor-associated antigens (TAA) and immune regulatory molecules. As a result, in the last few years, several bsAbs have been tested or are being tested in cancer patients. A few of them are currently approved for the treatment of some hematologic malignancies but no bsAbs are approved in solid tumors. In this review, we will provide an overview of the state-of-the-art of bsAbs for the treatment of solid malignancies outlining their classification, design, main technologies utilized for production, mechanisms of action, updated clinical evidence and potential limitations. |
format | Online Article Text |
id | pubmed-9694302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96943022022-11-26 Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors Liguori, Luigi Polcaro, Giovanna Nigro, Annunziata Conti, Valeria Sellitto, Carmine Perri, Francesco Ottaiano, Alessandro Cascella, Marco Zeppa, Pio Caputo, Alessandro Pepe, Stefano Sabbatino, Francesco Pharmaceutics Review Advancement in sequencing technologies allows for the identification of molecular pathways involved in tumor progression and treatment resistance. Implementation of novel agents targeting these pathways, defined as targeted therapy, significantly improves the prognosis of cancer patients. Targeted therapy also includes the use of monoclonal antibodies (mAbs). These drugs recognize specific oncogenic proteins expressed in cancer cells. However, as with many other types of targeting agents, mAb-based therapy usually fails in the long-term control of cancer progression due to the development of resistance. In many cases, resistance is caused by the activation of alternative pathways involved in cancer progression and the development of immune evasion mechanisms. To overcome this off-target resistance, bispecific antibodies (bsAbs) were developed to simultaneously target differential oncogenic pathway components, tumor-associated antigens (TAA) and immune regulatory molecules. As a result, in the last few years, several bsAbs have been tested or are being tested in cancer patients. A few of them are currently approved for the treatment of some hematologic malignancies but no bsAbs are approved in solid tumors. In this review, we will provide an overview of the state-of-the-art of bsAbs for the treatment of solid malignancies outlining their classification, design, main technologies utilized for production, mechanisms of action, updated clinical evidence and potential limitations. MDPI 2022-11-11 /pmc/articles/PMC9694302/ /pubmed/36432631 http://dx.doi.org/10.3390/pharmaceutics14112442 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Liguori, Luigi Polcaro, Giovanna Nigro, Annunziata Conti, Valeria Sellitto, Carmine Perri, Francesco Ottaiano, Alessandro Cascella, Marco Zeppa, Pio Caputo, Alessandro Pepe, Stefano Sabbatino, Francesco Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors |
title | Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors |
title_full | Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors |
title_fullStr | Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors |
title_full_unstemmed | Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors |
title_short | Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors |
title_sort | bispecific antibodies: a novel approach for the treatment of solid tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694302/ https://www.ncbi.nlm.nih.gov/pubmed/36432631 http://dx.doi.org/10.3390/pharmaceutics14112442 |
work_keys_str_mv | AT liguoriluigi bispecificantibodiesanovelapproachforthetreatmentofsolidtumors AT polcarogiovanna bispecificantibodiesanovelapproachforthetreatmentofsolidtumors AT nigroannunziata bispecificantibodiesanovelapproachforthetreatmentofsolidtumors AT contivaleria bispecificantibodiesanovelapproachforthetreatmentofsolidtumors AT sellittocarmine bispecificantibodiesanovelapproachforthetreatmentofsolidtumors AT perrifrancesco bispecificantibodiesanovelapproachforthetreatmentofsolidtumors AT ottaianoalessandro bispecificantibodiesanovelapproachforthetreatmentofsolidtumors AT cascellamarco bispecificantibodiesanovelapproachforthetreatmentofsolidtumors AT zeppapio bispecificantibodiesanovelapproachforthetreatmentofsolidtumors AT caputoalessandro bispecificantibodiesanovelapproachforthetreatmentofsolidtumors AT pepestefano bispecificantibodiesanovelapproachforthetreatmentofsolidtumors AT sabbatinofrancesco bispecificantibodiesanovelapproachforthetreatmentofsolidtumors |